Correction - Nine month report January-September 1999

Correction - Nine month report January-September 1999 The nine month report January-September 1999 published by Gambro contains the following incorrect figures. In a note to the income statement, amortization of goodwill is stated to amount to SEK 713 M. The correct figure is SEK 647 M. In the same note, depreciation of other assets is stated to amount to SEK 757 M. The correct figure is SEK 823 M. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Lars Granlöf, Senior Vice President, CFO, +46-8-613 65 00 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 42,000 patients in 565 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/21/19991021BIT00400/bit0001.doc http://www.bit.se/bitonline/1999/10/21/19991021BIT00400/bit0002.pdf